arrow_back Civic Audit
Share share

Home Infusion for Alpha-1 Antitrypsin Deficiency: New Medicare Coverage

This new act expands Medicare coverage to include home-based treatment for Alpha-1 Antitrypsin Deficiency. This means eligible individuals with this condition can receive necessary infusion therapy at home, improving access to care and potentially reducing financial burdens.
Key points
Medicare Part B will now cover Alpha-1 Antitrypsin Deficiency Disorder treatment (augmentation therapy) furnished in an individual's home.
The act also includes payment for intravenous administration kits and up to 2 hours of nursing services for home infusion therapy.
These changes take effect on January 1, 2023, for individuals enrolled in both Medicare Parts A and B, not in a Medicare Advantage plan.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 117_HR_7346
Sponsor: Rep. Salazar, Maria Elvira [R-FL-27]
Process start date: 2022-03-31
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

John W. Walsh Alpha-1 Home Infusion Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7346.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-31.

What are the main provisions?

Key points include:

  • Medicare Part B will now cover Alpha-1 Antitrypsin Deficiency Disorder treatment (augmentation therapy) furnished in an individual's home.
  • The act also includes payment for intravenous administration kits and up to 2 hours of nursing services for home infusion therapy.
  • These changes take effect on January 1, 2023, for individuals enrolled in both Medicare Parts A and B, not in a Medicare Advantage plan.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Salazar, Maria Elvira [R-FL-27].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Benefits